Delivery Order SPE2DB22D2007-SPE2DB25FH8CQ

Award Date 1/8/25
Potential Completion Date 1/9/25
Potential Value $61K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $14,050.99 firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The contract is for the supply of OZEMPIC 1 MG/DOSE (4 MG/3 ML) 3ML, a diabetes medication. The contract has an ultimate completion date of June 24, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This is a $18,859.14 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of OZEMPIC 2 MG/DOSE (8 MG/3 ML) 3ML, a diabetes medication, with a period of performance through February 7, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a wide range of...
This is a $33,278.34 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of OZEMPIC 2 MG/DOSE (8 MG/3 ML) 3ML, a medication used for diabetes management. The contract has an ultimate completion date of March 31, 2025. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This is a firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,566.67, is for the supply of OZEMPIC 2 MG/DOSE (8 MG/3 ML) 3ML, a specialty medication used for diabetes management. The contract has an ultimate completion date of February 4, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support...
This is a $59,171.21 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of OZEMPIC 1 MG/DOSE (4 MG/3 ML) 3ML, a medication used to treat type 2 diabetes. The contract has an ultimate completion date of April 4, 2025. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This is a $31,608.15 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of OZEMPIC 2 MG/DOSE (8 MG/3 ML) 3ML, a medication used to treat diabetes. The contract has an ultimate completion date of February 25, 2025. There is no set-aside designation for this contract. AmerisourceBergen holds a significant $999,999,999...
This is a $12,454.21 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The award is for the supply of OZEMPIC 1 MG/DOSE (4 MG/3 ML) 3ML, a medication used to treat diabetes. The order has an ultimate completion date of January 23, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This is a $22,648.66 firm-fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of OZEMPIC 2 MG/DOSE (8 MG/3 ML) 3ML, a diabetes medication, with a period of performance through April 8, 2025. The contract was not set aside for any specific business type. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This is a $7,879.56 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of OZEMPIC 1 MG/DOSE (4 MG/3 ML) 3ML, which is a medication used for the treatment of diabetes. The contract has an ultimate completion date of June 14, 2024. AmerisourceBergen Drug Corp is a for-profit organization registered in the System for Award Management...
This is a $30,795.71 firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of OZEMPIC 1 MG/DOSE (4 MG/3 ML) 3ML, a medication used to treat diabetes. The delivery order has a completion date of July 29, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
  • SPE2DB22D2007
    Indefinite Delivery Contract
  • SPE2DB22D2007-SPE2DB25FH8CQ
    Delivery Order

This is a $61,024.67 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of OZEMPIC 2 MG/DOSE (8 MG/3 ML) 3ML, a medication used in the treatment of diabetes. The contract has an ultimate completion date of January 9, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 5/21/25, 10:22 AM